In in vitro studies, three features of 3039-0164’s anticancer effect against NSCLC were investigated: PRMT5 enzyme activity; expression of two target genes, FGFR3 and elF4E; and FGFR3-mediated downstream signaling pathways. This evidence concerns the gene FGFR3 and non-small cell lung carcinoma.